Number: GOG 229K Principal Investigator: Mutch, David
Title: A Phase II Evaluation of BIBF 1120 (IND #113086) In The Treatment of Recurrent or Persistent Endometrial Carcinoma
Phase: II Disease Site: Corpus Uteri
Participating Site(s):
Contact: 800-600-3606 or

The purpose of this study is to determine the effectiveness of the investigational drug BIBF 1120 in treating your type of cancer and to determine the types and severity of side effects caused by this treatment. BIBF 1120 is not an FDA (Food and Drug Administration) approved drug and therefore the use of BIBF 1120 in the treatment of endometrial cancer is experimental. The reason this drug is being looked at for treatment in endometrial cancer is that it has demonstrated its ability to stop three proteins from working: vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). These three proteins work by turning on (stimulating) the growth of tumor cells. By stopping the three proteins from working, the BIBF 1120 may cause the cancer to shrink by stopping the growth of tumor blood vessels and tumor cells.
More Information:
Internal Protocol Documents (requires Siteman administrative database password)